Purpose: To evaluate the effect of a regenerative agent (RGTA) [Cacicol20-poly(carboxymethyl glucose sulfate); OTR3, Paris, France] on corneal reepithelialization and pain after corneal crosslinking (CXL) for keratoconus.
C orneal cross-linking (CXL) is a surgical technique used to strengthen ectatic cornea tissue, involving epithelial debridement and application of riboflavin and ultraviolet-A irradiation (UVA). [1] [2] [3] [4] The standard CXL protocol requires corneal epithelial removal, which retains the drawback of postoperative pain and the risk of epithelium-related complications such as infection and recurrent erosions. Cacicol20 [poly(carboxymethyl glucose sulfate); OTR3, Paris, France] is a regenerative agent (RGTA) that has provided encouraging results in corneal lesions such as neurotrophic ulcers, chronic neurotrophic keratitis, and persistent epithelial defects. [5] [6] [7] [8] The agent contains carboxymethyl dextran sulfate polymer, engineered to replace heparan sulfates, and seems to be effective in enhancing reepithelialization, restoring extracellular matrix architecture, and reducing pain. 5, 6 These effects would be beneficial to eliminate the drawbacks of the epithelium-off CXL protocol. Rapid corneal reepithelialization after CXL has a key role in minimizing possible complications related to corneal wound healing.
The purpose of this study was to evaluate the efficacy of the RGTA (Cacicol20) in corneal reepithelialization and postoperative pain by comparing the epithelial defect size and the level of pain between the study eye (instillation of the RGTA) and control eye (instillation of artificial tears) in a series of patients with keratoconus who underwent bilateral CXL treatment.
PATIENTS AND METHODS
In this prospective comparative (contralateral) study, patients with progressive keratoconus were enrolled. The clinical diagnosis of keratoconus was based on corneal topography data (iTrace; Tracey Technologies, Houston, TX). Inclusion criteria were progressive keratoconus, patient age .18 years, corneal thickness .400 mm, no other ocular pathological signs, and no pregnancy or lactation. Keratoconus was graded with the Amsler-Krumeich classification; only patients with grade I and II were included in this study. Keratoconus was described as progressive when there had been an increase in the cone apex keratometry (K) of 0.75 diopter (D) or an alteration of 0.75 D in the spherical equivalent refraction in the previous 6 months.
All patients underwent bilateral CXL treatment according to the Cretan protocol. 9 One eye of each patient was randomly instilled with an RGTA (Cacicol20) (study eye; 1 drop daily until complete reepithelialization), whereas the fellow eye was instilled with artificial tears (control eye; 1 drop daily until complete reepithelialization) in addition to the standard postoperative medication. The patient and the ophthalmologist who performed the postoperative examinations were masked to which eye the RGTA or artificial tears were instilled. All patients were appropriately informed before their participation in the study and gave written informed consent. The research conformed to the tenets of the Declaration of Helsinki and the Institutional Review Board.
Surgical Technique
All procedures were performed in our institute by the same surgeon (G.D.K.) under sterile conditions. After administration of topical anesthesia comprising proxymetacaine hydrochloride 0.5% eyedrops (Alcaine; Alcon Laboratories, Inc, Fort Worth, TX), the corneal epithelium was removed by transepithelial phototherapeutic keratectomy (PTK) using the Allegretto WaveLight excimer laser (WaveLight Laser Technologie AG). Transepithelial PTK ablation was performed at a 7.0-mm zone at an intended depth of 45 mm. After epithelial removal, riboflavin (0.1% solution of 10 mg riboflavin-5-phosphate in 10 mL dextran-T-500 20% solution; Medicross, Medio-Haus, Behrensbrook, Neudorf, Germany) was instilled on the center of the cornea every 3 minutes for approximately 30 minutes. Ultraviolet A (UVA) irradiation was performed using a UVA optical system (CCL-365; Peschke Meditrade GmbH). Before treatment, an intended irradiance of 9.0 mW/cm 2 was calibrated using the UVA light meter YK-34UV (Lutron Electronic; Enterprise Co, Ltd, Taipei, Taiwan), which is supplied with the UV-X device. Irradiance was performed for 10 minutes, corresponding to a total surface dose of 5.4 J/cm 2 . During UVA irradiation, riboflavin solution was applied every 3 minutes to maintain corneal saturation with riboflavin. At the end of the procedure, a silicone-hydrogel bandage contact lens (BCL) (Lotrafilcon B, Air Optix; Ciba Vision, Duluth; GA) was applied until full reepithelialization.
Postoperative Medication
Postoperative medication included ofloxacin (Exocin; Allergan Pharmaceuticals Ltd) 4 times daily and chloramphenicol/dexamethasone drops (Dispersadron; Thea Laboratories, Inc) 4 times daily in both eyes until the removal of the BCL. Patients were encouraged to use artificial tears at least 6 times per day. In addition to the standard early postoperative medication, the study eye was also instilled with Cacicol20 (one drop daily), whereas the fellow eye was instilled with artificial tears (one drop daily) until complete reepithelialization.
Postoperative Follow-up
All patients were examined daily until complete reepithelialization. Each postoperative daily examination included slit-lamp biomicroscopy to objectively assess epithelial healing (epithelial defect size). An ophthalmologist (unaware of which eye was instilled with RGTAs or artificial tears) performed the assessments. The epithelial defect size was calculated using the mean radius of the long and short axes of the remaining area. Other researchers have used this method to determine the remaining epithelial defect size. 10 After full reepithelialization, the BCL was removed and fluorescein was instilled to confirm the absence of an epithelial defect.
Subjective evaluation of pain (discomfort) was recorded on every postoperative day until complete reepithelialization. The pain score was evaluated on a scale of 0 to 4 as follows: 0 = no discomfort or pain; 1 = mild discomfort; 2 = moderate burning pain; 3 = burning pain requiring oral medication; 4 = severe constant or sharp pain not mitigated with oral medication.
Statistical Analysis
All data were collected in an Excel spreadsheet (Microsoft, Redmond, WA). SPSS software for Windows version 20 (SPSS, Inc, Chicago, IL) was used for statistical analysis of the results. Continuous variables are presented as mean 6 SD. P , 0.05 is considered statistically significant. A sample size analysis (G*Power 3.1.3; Franz Paul, Universität Kiel, Germany) was performed for a 2-tailed t test with a large difference effect size, with a statistical power of 85% and a statistical significance level of 0.05, resulting in 18 patients participating in this prospective comparative (contralateral) study. Subjective and objective outcomes were compared using the paired Student t test and x 2 test, where appropriate.
RESULTS
Thirty-six eyes of 18 patients (14 men and 4 women) were included in this prospective comparative (contralateral) study. Mean patient age was 24.1 6 4.4 years (range, 18-34 years). No intraoperative or early postoperative complications were observed in any of the patients.
Eyes of the study group had smaller areas of epithelial defects than did the eyes of the control group at all postoperative follow-up visits. In particular, statistically significant differences were observed for epithelial defect size measurements between the study group (RGTA; Cacicol20) and control group (artificial tears) at day 1 (study group: 19.6 6 4.2 mm 2 versus control group: 21.5 6 2.8 mm 2 ; P = 0.019) and day 2 (study group: 6.4 6 3.4 mm 2 vs. control group: 7.9 6 4.3 mm 2 ; P = 0.014) postoperatively (Fig. 1) .
At day 3 postoperatively, 61.1% (11/18) of eyes of the study group were fully reepithelialized, compared with 11.1% (2/18) of eyes of the control group (x 2 = 9.753, P = 0.002). At day 4 postoperatively, 100% (18/18) of eyes of the study group were fully reepithelialized, compared with 77.8% (14/ 18) of eyes of the control group. In 13 patients, the study eye healed 1 day earlier and in 1 patient 2 days earlier than the control contralateral eye. There was no statistically significant difference between the study and control groups in the pain index in any postoperative day (P . 0.05; Fig. 2 ).
DISCUSSION
The standard CXL protocol requires corneal epithelial removal. 2, 4 Rapid corneal wound healing (reepithelialization process) is an important factor in minimizing the risk of epithelium-related complications such as infection and recurrent erosions and postoperative pain. 4 The RGTA (Cacicol20) is a large biopolymer that binds matrix proteins that affect corneal healing. 11 The molecular activity of RGTAs has been described to involve the imitation of heparan sulfate molecules. 5, 11 The RGTA retrieves the role of these molecules, restoring the extracellular microenvironment and improving the production of signals and essential growth factors for tissue healing. 11 Previous studies have demonstrated the safety and efficacy of the RGTA (Cacicol20) in restoring several lesions of the corneal surface. The RGTA has already been used as a monotherapy for neurotrophic corneal ulcers and chronic neurotrophic keratitis providing encouraging results. [5] [6] [7] In our recent study, the combination of the RGTA (Cacicol20) with a BCL has been proved an efficacious therapeutic approach for persistent epithelial defects (unresponsive to conventional treatments for 4-8 weeks). 8 Contact lenses have shown beneficial effects on epithelial defects, and their combined application with the RGTA (Cacicol20) revealed effective results, because all patients had a short period of corneal epithelial healing (4-21 days). 8, 10 Daily application had a favorable tolerance, and no side effects were noted. 8 Moreover, the integrity of the corneal epithelium remained, and no recurrence occurred during the follow-up period. 8 In this study, the RGTA (Cacicol20) seemed to have a beneficial role in epithelial healing on most of the eyes of the study group compared with the eyes of the control group, during the reepithelialization process at the early postoperative period after CXL. Eyes instilled with the RGTA (Caciol20) (study group) had smaller areas of epithelial defects than did the eyes instilled with artificial tears (control group) on postoperative days 1 and 2. At postoperative day 3, 61.1% of eyes of the study group were fully reepithelialized compared with 11.1% of eyes of the control group (P = 0.002). At postoperative day 4, all eyes of the study group were fully reepithelialized compared with 77.8% of eyes of the control group. However, the statistically significant differences between the 2 groups regarding the epithelial defect size and time of complete reepithelialization do not necessarily imply strong clinical significance. Regarding the evaluation of pain, no significant difference was observed between the 2 groups at any postoperative day. This aspect is possibly biased, because of the use of contact lenses postoperatively, in both control and study groups.
A possible explanation of our findings could be a potential role of the RGTA (Cacicol20) in structural and cellular alterations occurring in the immediate period after the CXL procedure. In the irradiated area, stromal edema and a mild inflammatory reaction have been described as early responses to riboflavin and UVA irradiation. 12, 13 Histological studies have shown several effects of the RGTA (Cacicol20) including amelioration of tissue edema, fibrosis, and inflammation, thereby improving wound repair. 14, 15 Our study findings indicate that the RGTA (Cacicol20) could possibly promote-accelerate the reepithelialization process after CXL treatment. Moreover, this is the first study that compares the RGTA (Cacicol20) effect on nonpathological corneal epithelium, in addition to previously published articles that described the effect of the agent in pathological conditions such as neurotrophic ulcers and PEDs. 5, 6, 8 In conclusion, the results of our study suggest that the addition of the RGTA (Cacicol20) to the standard postoperative medication after CXL could be an effective approach to enhance the epithelial recovery. To the best of our knowledge, this is the first clinical study evaluating the possible potential effect of the RGTA (Cacicol20) on corneal reepithelialization after CXL treatment. Larger patient series are necessary to evaluate the efficacy of this treatment protocol in clinical practice.
